Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kiyoshi Yoshimura

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
In Vivo (Athens, Greece)|April 29, 2021
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric CancerYutaro Kubota, Kiyoshi Yoshimura, Kazuyuki Hamada, et al.
Cancer Research|January 21, 2006
Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenesKiyoshi Yoshimura, Ajay Jain, Heather E Allen, et al.
Journal for Immunotherapy of Cancer|September 14, 2023
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)Jun Masuda, Hitomi Sakai, Junji Tsurutani, et al.
Anticancer Research|July 26, 2017
Correlation Between NKG2DL Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse ModelsAyano Konagai, Kiyoshi Yoshimura, Shouichi Hazama, et al.
Cancer Science|August 26, 2016
Calreticulin is highly expressed in pancreatic cancer stem-like cellsSatoshi Matsukuma, Kiyoshi Yoshimura, Tomio Ueno, et al.
Anticancer Research|October 1, 2021
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 ImmunotherapyKazuyuki Hamada, Kiyoshi Yoshimura, Yuya Hirasawa, et al.
Oncology Letters|August 10, 2023
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapyRyotaro Ohkuma, Yuki Fujimoto, Katsuaki Ieguchi, et al.
Oncology Letters|February 3, 2018
Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomyRyoji Kamei, Kiyoshi Yoshimura, Shigefumi Yoshino, et al.
Frontiers in Immunology|September 24, 2025
Tumor <i>Akkermansia muciniphila</i> predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expressionTakashi Shimizu, Ryotaro Ohkuma, Mayumi Homma, et al.
International Journal of Oncology|December 28, 2020
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
In Vivo (Athens, Greece)|April 29, 2021
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric CancerYutaro Kubota, Kiyoshi Yoshimura, Kazuyuki Hamada, et al.
Cancer Research|January 21, 2006
Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenesKiyoshi Yoshimura, Ajay Jain, Heather E Allen, et al.
Journal for Immunotherapy of Cancer|September 14, 2023
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)Jun Masuda, Hitomi Sakai, Junji Tsurutani, et al.
Anticancer Research|July 26, 2017
Correlation Between NKG2DL Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse ModelsAyano Konagai, Kiyoshi Yoshimura, Shouichi Hazama, et al.
Cancer Science|August 26, 2016
Calreticulin is highly expressed in pancreatic cancer stem-like cellsSatoshi Matsukuma, Kiyoshi Yoshimura, Tomio Ueno, et al.
Anticancer Research|October 1, 2021
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 ImmunotherapyKazuyuki Hamada, Kiyoshi Yoshimura, Yuya Hirasawa, et al.
Oncology Letters|August 10, 2023
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapyRyotaro Ohkuma, Yuki Fujimoto, Katsuaki Ieguchi, et al.
Oncology Letters|February 3, 2018
Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomyRyoji Kamei, Kiyoshi Yoshimura, Shigefumi Yoshino, et al.
Frontiers in Immunology|September 24, 2025
Tumor <i>Akkermansia muciniphila</i> predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expressionTakashi Shimizu, Ryotaro Ohkuma, Mayumi Homma, et al.
International Journal of Oncology|December 28, 2020
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Pageof 11